Table 1.
Demographics and clinical characteristics of patients with iCCA
| Characteristics | FGFR2 fusions (n = 15) | No FGFR2 alterations (n = 115) | All patients with iCCA (n = 132)a |
|---|---|---|---|
| Age at diagnosis, median (range), years | 58.0 (36–73) | 64.0 (28–86) | 62.0 (28–86) |
| < 40, n (%) | 2 (13.3) | 5 (4.3) | 7 (5.3) |
| 40 to <65, n (%) | 10 (66.7) | 55 (47.8) | 66 (50.0) |
| ≥ 65, n (%) | 3 (20.0) | 55 (47.8) | 59 (44.7) |
| Sex, n (%) | |||
| Male | 6 (40.0) | 53 (46.1) | 60 (45.5) |
| Female | 9 (60.0) | 62 (53.9) | 72 (54.5) |
| Race, n (%) | |||
| Evaluable, n | 14 | 106 | 121 |
| White | 12 (85.7) | 96 (90.6) | 109 (90.1) |
| Black | 1 (7.1) | 5 (4.7) | 6 (5.0) |
| Asian | 1 (7.1) | 5 (4.7) | 6 (5.0) |
| Prior resection, n (%) | |||
| Yes | 5 (33.3) | 36 (31.3) | 42 (31.8) |
| No | 10 (66.7) | 79 (68.7) | 90 (68.2) |
| Disease stage at diagnosis, n (%) | |||
| 1 | 3 (20.0) | 9 (7.8) | 13 (9.8) |
| 2 | 0 | 18 (15.7) | 18 (13.6) |
| 3 | 3 (20.0) | 26 (22.6) | 30 (22.7) |
| 4 | 9 (60.0) | 62 (53.9) | 71 (53.8) |
| Number of treatment lines following initial diagnosis, n (%) | |||
| Evaluable, n | 15 | 111 | 128 |
| 0 | 0 | 4 (3.6) | 4 (3.1) |
| 1 | 4 (26.7) | 26 (23.4) | 31 (24.2) |
| 2 | 1 (6.7) | 29 (26.1) | 31 (24.2) |
| 3 | 3 (20.0) | 32 (28.8) | 35 (27.3) |
| >3 | 7 (46.7) | 20 (18.0) | 27 (21.1) |
| 1L treatment, n (%) | |||
| Evaluable, n | 15 | 99 | 115 |
| Platinum basedb | 14 (93.3) | 92 (92.9) | 107 (93.0) |
| Non-platinum basedc | 1 (6.7) | 7 (7.1) | 8 (7.0) |
| 2L treatment, n (%) | |||
| Evaluable, n | 11 | 77 | 89 |
| Pyrimidine based | 7 (63.6) | 45 (58.4) | 53 (59.6) |
| Pyrimidine/platinum | 1 (9.1) | 17 (22.1) | 18 (20.2) |
| Other | 3 (27.3) | 15 (19.5) | 18 (20.2) |
| Duration of 1L therapy | |||
| Evaluable, n | 13 | 89 | 103 |
| Overall, median (range), days | 105.0 (43–770) | 140.0 (1–1114) | 139.0 (1–1114) |
| Evaluable, n | 10 | 70 | 81 |
| Platinum-based, median (range), days | 98.0 (43–770) | 175.0 (1–1114) | 141.0 (1–1114) |
| Evaluable, n | 3 | 19 | 22 |
| Non-platinum-based, median (range), days | 169.0 (97–505) | 113.0 (36–751) | 117.0 (36–751) |
| Duration of 2L therapy | |||
| Evaluable, n | 10 | 71 | 82 |
| Overall, median (range), days | 185.5 (80–1149) | 76.0 (1–2584) | 93.5 (1–2584) |
1L first-line, 2L second-line, FGFR2 fibroblast growth factor receptor 2, iCCA intrahepatic cholangiocarcinoma
aTwo patients with other FGFR2 alterations are not presented
bGemcitabine + cisplatin; gemcitabine, cisplatin + other therapy; gemcitabine, platinum therapy (not cisplatin) + other therapy; or platinum therapy + other therapy
cGemcitabine monotherapy; gemcitabine, nonplatinum therapy + other therapy; or other therapy